FDA — authorised 6 March 2013
- Application: NDA202008
- Marketing authorisation holder: AVID RADIOPHARMS INC
- Indication: Manufacturing (CMC)
- Status: approved
FDA authorised Amyvid on 6 March 2013
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. FDA authorised it on 6 March 2013.
AVID RADIOPHARMS INC holds the US marketing authorisation.